Piper Jaffray upgraded Simcere Pharmaceutical (NYSE: SCR) from Neutral to Buy with an $18 price target, in transferred coverage.

This article: 116 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE